# US 2015/0148397 A1 · Clonidine formulations in a biodegradable polymer carrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148397 A1
- Document ID: US20150148397A1
- Status: Published application
- Kind: A1
- Application number: 14/608,981
- Filed: 2015-01-29
- Published: 2015-05-28
- Earliest claimed: 2008-04-18
- Assignees: Warsaw Orthopedic, Inc.
- Applicants: Warsaw Orthopedic, Inc.
- Inventors: John M. Zanella; Christopher M. Hobot; Danielle L. Biggs; Katara Shaw; Phillip Edward McDonald; Vanja Margareta King; William F. McKay; Kathy L. Remsen
- Web page: https://patentgrep.com/patent/US20150148397A1

## CPC

- A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/204: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/4162: condensed with heterocyclic ring systems
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

## Claims

### Claim 1

An implantable drug depot for reducing, preventing or treating pain in a patient in need of such treatment, the implantable drug depot comprising clonidine in an amount from about 1 wt. % to about 20 wt. % of the drug depot, and at least one biodegradable polymer, wherein the drug depot is capable of releasing clonidine over a period of at least three days.

### Claim 2 (depends on 1)

An implantable drug depot according to claim 1, wherein said clonidine comprises from about 5 wt. % to about 15 wt. % of the drug depot.

### Claim 3 (depends on 1)

An implantable drug depot according to claim 1, wherein said at least one biodegradable polymer comprises at least 70 wt. % of the drug depot.

### Claim 4 (depends on 1)

An implantable drug depot according to claim 1, wherein said at least one biodegradable polymer comprises at least 90 wt. % of the drug depot.

### Claim 5 (depends on 1)

An implantable drug depot according to claim 1, wherein the at least one biodegradable polymer comprises one or more of poly(lactide-co-glycolide) (PLGA), polylactide (PLA), polyglycolide (PGA), D-lactide, D,L-lactide, L-lactide, D,L-lactide-co-caprolactone, D,L-lactide-co-glycolide-co-caprolactone or a combination thereof.

### Claim 6 (depends on 5)

An implantable drug depot according to claim 5 wherein the at least one biodegradable polymer comprises poly(lactic-co-glycolide) and said poly(lactic-co-glycolide) comprises a mixture of polyglycolide and polylactide.

### Claim 7 (depends on 6)

An implantable drug depot according to claim 6 wherein said mixture comprises more polylactide than polyglycolide.

### Claim 8 (depends on 1)

An implantable drug depot according to claim 1, wherein said clonidine is in the form of clonidine hydrochloride or a mixture of clonidine base and a hydrochloride salt.

### Claim 9 (depends on 1)

An implantable drug depot according to claim 1, wherein the drug depot releases:
(i) a bolus dose of the clonidine at a site beneath the skin; and (ii) an effective amount of the clonidine over a period of at least fifty days.

### Claim 10 (depends on 1)

An implantable drug depot according to claim 1, wherein the at least one biodegradable polymer comprises poly(lactic-co-glycolide) or poly(orthoester) or a combination thereof, and said at least one biodegradable polymer comprises at least 70 wt. % of said drug depot.

### Claim 11

An implantable drug depot for reducing, preventing or treating pain in a patient in need of such treatment, the implantable drug depot comprising clonidine hydrochloride in an amount of from about 1 wt. % to about 20 wt. % of the drug depot, and at least one polymer, wherein the at least one polymer comprises one or more of poly(lactide-co-glycolide) (PLGA), polylactide (PLA), polyglycolide (PGA), D-lactide, D,L-lactide, L-lactide, D,L-lactide-co-caprolactone, D,L-lactide-co-glycolide-co-caprolactone or a combination thereof.

### Claim 12

A method for treating acute pain, wherein said method comprises implanting a drug depot in an organism to reduce, prevent or treat pain, wherein said drug depot comprises clonidine in an amount from about 1 wt. % to about 20 wt. % of the drug depot, and at least one biodegradable polymer.

### Claim 13 (depends on 12)

A method according to claim 12, wherein said clonidine comprises from about 5 wt. % to about 15 wt. % of the drug depot.

### Claim 14 (depends on 12)

A method according to claim 12, wherein said biodegradable polymer comprises at least 70 wt. % of the drug depot.

### Claim 15 (depends on 12)

A method according to claim 12, wherein said biodegradable polymer comprises at least 90 wt. % of the drug depot.

### Claim 16 (depends on 12)

A method according to claim 12, wherein the at least one biodegradable polymer comprises one or more of poly(lactide-co-glycolide) (PLGA), polylactide (PLA), polyglycolide (PGA), D-lactide, polyorthoester (POE), D,L-lactide, L-lactide, D,L-lactide-co-caprolactone, D,L-lactide-co-glycolide-co-caprolactone or a combination thereof.

### Claim 17 (depends on 16)

A method according to claim 16, wherein the at least one biodegradable polymer comprises poly(lactic-co-glycolide) and said poly(lactic-co-glycolide) comprises a mixture of polyglycolide and polylactide.

### Claim 18 (depends on 17)

A method according to claim 17, wherein said mixture comprises more polylactide than polyglycolide.

### Claim 19 (depends on 12)

A method according to claim 12, wherein said clonidine is in the form of clonidine hydrochloride or a mixture of clonidine and a hydrochloride salt.

### Claim 20 (depends on 12)

A method according to claim 12, wherein said implanting comprises applying a said pharmaceutical composition at a plurality of sites that triangulate a pain generator.
